NZ620000A - Prodrug forms of kinase inhibitors and their use in cancer therapy - Google Patents
Prodrug forms of kinase inhibitors and their use in cancer therapyInfo
- Publication number
- NZ620000A NZ620000A NZ620000A NZ62000010A NZ620000A NZ 620000 A NZ620000 A NZ 620000A NZ 620000 A NZ620000 A NZ 620000A NZ 62000010 A NZ62000010 A NZ 62000010A NZ 620000 A NZ620000 A NZ 620000A
- Authority
- NZ
- New Zealand
- Prior art keywords
- kinase inhibitors
- prodrug forms
- cancer therapy
- compounds
- prodrug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ620000A NZ620000A (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in cancer therapy |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ57549009 | 2009-03-11 | ||
| NZ57945809 | 2009-09-02 | ||
| NZ58117009 | 2009-11-12 | ||
| NZ595206A NZ595206A (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in therapy |
| NZ620000A NZ620000A (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ620000A true NZ620000A (en) | 2015-07-31 |
Family
ID=42728538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ620000A NZ620000A (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in cancer therapy |
| NZ595206A NZ595206A (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595206A NZ595206A (en) | 2009-03-11 | 2010-03-11 | Prodrug forms of kinase inhibitors and their use in therapy |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9073916B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3031807A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5793428B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110130468A (cg-RX-API-DMAC7.html) |
| CN (2) | CN102348708A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010221818A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1011505A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2754808C (cg-RX-API-DMAC7.html) |
| IL (1) | IL214626A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011009034A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ620000A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2011141121A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010104406A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
| EP3488866A1 (en) | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2531322T3 (es) | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| EP3175853B1 (en) | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| RU2011141121A (ru) | 2009-03-11 | 2013-04-20 | Окленд Юнисервисиз Лимитед | Пролекарственные формы ингибиторов киназ и их применение в терапии |
| PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
| BR112012004720B1 (pt) * | 2009-09-02 | 2021-06-29 | Auckland Uniservices Limited | Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende |
| CN102558185B (zh) * | 2010-12-09 | 2016-02-10 | 中国科学院上海药物研究所 | 吡啶并吡咯三嗪化合物、其制备方法和用途 |
| CN102838590B (zh) * | 2011-06-21 | 2014-07-09 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| WO2013152135A1 (en) * | 2012-04-04 | 2013-10-10 | Dawei Zhang | Substituted quinolines as bruton's tyrosine kinases inhibitors |
| CN105796562A (zh) * | 2012-09-10 | 2016-07-27 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| CN105796569A (zh) * | 2012-09-10 | 2016-07-27 | 杨子娇 | 化合物在制备防治青光眼病的药物中的用途 |
| CN103664797A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103655576A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN103724349A (zh) * | 2012-10-11 | 2014-04-16 | 韩冰 | 一类治疗脑性瘫痪的化合物及其用途 |
| CN102952095A (zh) * | 2012-10-19 | 2013-03-06 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法 |
| CN103784456A (zh) * | 2012-10-31 | 2014-05-14 | 韩冰 | 一类治疗干眼症的化合物及其用途 |
| CN103787986A (zh) * | 2012-10-31 | 2014-05-14 | 韩冰 | 一类治疗干眼症的化合物及其用途 |
| CN103804304A (zh) * | 2012-11-01 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804305A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103804306A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
| CA2903394C (en) * | 2013-03-14 | 2021-08-31 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2986294A4 (en) | 2013-04-17 | 2016-11-16 | Biopharma Works | PROCESS FOR PAIN TREATMENT |
| EP2986295A4 (en) * | 2013-04-17 | 2016-11-09 | Biopharma Works | PROCESS FOR PAIN TREATMENT |
| CN107892684B (zh) * | 2013-07-18 | 2020-05-26 | 锦州奥鸿药业有限责任公司 | 喹唑啉衍生物及其药物组合物,以及作为药物的用途 |
| CN107427515B (zh) | 2014-12-03 | 2021-11-16 | 奥克兰联合服务有限公司 | 用于治疗癌症的激酶抑制剂前药 |
| US20160376239A1 (en) * | 2015-06-29 | 2016-12-29 | Ontogenesis, Llc | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use |
| CN110809576B (zh) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | Fgfr激酶抑制剂和药物用途 |
| CN107569491A (zh) * | 2017-08-30 | 2018-01-12 | 杭州科兴生物化工有限公司 | 一种星孢菌素类化合物的应用 |
| CN111527103A (zh) | 2017-09-08 | 2020-08-11 | 科罗拉多大学董事会,法人团体 | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 |
| WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
| CA3088997A1 (en) * | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| WO2021003339A1 (en) | 2019-07-03 | 2021-01-07 | The Regents Of The University Of Colorado, A Body Corporate | Amp-activated protein kinase inhibitors and methods of making and using the same |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| WO2022006412A2 (en) | 2020-07-02 | 2022-01-06 | The Regents Of The University Of Colorado, A Body Corporate | Conjugates of ampk inhibitors and protac degraders and related uses |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE236881T1 (de) | 1995-08-18 | 2003-04-15 | Auckland Uniservices Ltd | Durch strahlung aktivierte cytotoxin therapie |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6355636B1 (en) | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| ES2279361T3 (es) | 2003-04-16 | 2007-08-16 | F. Hoffmann-La Roche Ag | Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide. |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| HRP20110958T1 (hr) | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| GB0421294D0 (en) | 2004-09-24 | 2004-10-27 | Angiogene Pharm Ltd | Bioreductively-activated prodrugs |
| CA2629249C (en) * | 2005-11-11 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| WO2008039087A2 (en) | 2006-09-29 | 2008-04-03 | Auckland Uniservices Limited | Indoline derivatives and uses thereof |
| WO2008151253A1 (en) | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| RU2011141121A (ru) | 2009-03-11 | 2013-04-20 | Окленд Юнисервисиз Лимитед | Пролекарственные формы ингибиторов киназ и их применение в терапии |
-
2010
- 2010-03-11 RU RU2011141121/04A patent/RU2011141121A/ru not_active Application Discontinuation
- 2010-03-11 MX MX2011009034A patent/MX2011009034A/es unknown
- 2010-03-11 JP JP2011553972A patent/JP5793428B2/ja active Active
- 2010-03-11 WO PCT/NZ2010/000040 patent/WO2010104406A1/en not_active Ceased
- 2010-03-11 AU AU2010221818A patent/AU2010221818A1/en not_active Abandoned
- 2010-03-11 KR KR1020117023889A patent/KR20110130468A/ko not_active Ceased
- 2010-03-11 US US13/138,429 patent/US9073916B2/en active Active
- 2010-03-11 NZ NZ620000A patent/NZ620000A/en not_active IP Right Cessation
- 2010-03-11 NZ NZ595206A patent/NZ595206A/en not_active IP Right Cessation
- 2010-03-11 CN CN2010800114500A patent/CN102348708A/zh active Pending
- 2010-03-11 EP EP16150071.5A patent/EP3031807A1/en not_active Withdrawn
- 2010-03-11 CA CA2754808A patent/CA2754808C/en active Active
- 2010-03-11 CN CN201610031117.5A patent/CN105541836A/zh active Pending
- 2010-03-11 BR BRPI1011505A patent/BRPI1011505A2/pt not_active IP Right Cessation
- 2010-03-11 EP EP10751067.9A patent/EP2406262B1/en active Active
-
2011
- 2011-08-11 IL IL214626A patent/IL214626A0/en unknown
-
2015
- 2015-06-04 US US14/731,309 patent/US20160002222A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1011505A2 (pt) | 2016-03-22 |
| CN102348708A (zh) | 2012-02-08 |
| KR20110130468A (ko) | 2011-12-05 |
| JP2012520295A (ja) | 2012-09-06 |
| EP3031807A1 (en) | 2016-06-15 |
| US9073916B2 (en) | 2015-07-07 |
| EP2406262B1 (en) | 2016-02-17 |
| WO2010104406A1 (en) | 2010-09-16 |
| RU2011141121A (ru) | 2013-04-20 |
| NZ595206A (en) | 2014-02-28 |
| CA2754808C (en) | 2019-01-08 |
| US20160002222A1 (en) | 2016-01-07 |
| US20120077811A1 (en) | 2012-03-29 |
| AU2010221818A1 (en) | 2011-10-06 |
| IL214626A0 (en) | 2011-09-27 |
| JP5793428B2 (ja) | 2015-10-14 |
| CN105541836A (zh) | 2016-05-04 |
| CA2754808A1 (en) | 2010-09-16 |
| EP2406262A4 (en) | 2012-06-20 |
| MX2011009034A (es) | 2011-09-22 |
| EP2406262A1 (en) | 2012-01-18 |
| WO2010104406A8 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| PH12013500064A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| MX2013012977A (es) | Derivados de tiazol. | |
| JO2848B1 (en) | Organic compounds | |
| MX352975B (es) | Piridina y derivados de pirazina. | |
| PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
| MY170823A (en) | Protein kinase inhibitors | |
| TN2011000291A1 (en) | Purine compounds | |
| MX2013011329A (es) | Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso. | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| TN2011000293A1 (en) | Protein kinase inhibitors | |
| ZA201000085B (en) | 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors | |
| MX2009008132A (es) | Terapia de combinacion con inhibidores de angiogenesis. | |
| UA98141C2 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| MY163202A (en) | Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof | |
| PH12013501754A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
| IN2014MN02082A (cg-RX-API-DMAC7.html) | ||
| NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| MY150493A (en) | Quinazoline derivatives | |
| MY162934A (en) | Anticancer steroidal lactones unsaturated in position 7 (8) | |
| MX2013015357A (es) | Terapia de combinacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 MAR 2017 BY AJ PARK Effective date: 20160310 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2018 BY PATRIX IP SERVICES Effective date: 20170517 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2019 BY PATRIX IP SERVICES Effective date: 20180224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2020 BY CPA GLOBAL Effective date: 20190124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2022 BY COMPUTER PACKAGES INC. Effective date: 20210306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2023 BY COMPUTER PACKAGES INC Effective date: 20220217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2024 BY COMPUTER PACKAGES INC Effective date: 20230217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2025 BY DENNEMEYER + CO. S.A R.L. Effective date: 20240403 |
|
| LAPS | Patent lapsed |